Nkarta (NASDAQ:NKTX - Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
Nkarta Price Performance
NKTX traded down $0.06 on Friday, reaching $1.66. 1,190,980 shares of the company's stock were exchanged, compared to its average volume of 1,042,579. Nkarta has a twelve month low of $1.57 and a twelve month high of $13.90. The stock has a market cap of $117.14 million, a PE ratio of -0.88 and a beta of 0.90. The stock's fifty day moving average price is $2.14 and its 200-day moving average price is $3.11.
Insider Buying and Selling
In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.70% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Separately, Mizuho lowered their target price on Nkarta from $20.00 to $16.00 and set an "outperform" rating on the stock in a report on Thursday, November 21st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $15.00.
Check Out Our Latest Stock Analysis on NKTX
Nkarta Company Profile
(
Get Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Featured Articles
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
